Stifel analyst Justin Keywood lowered the firm’s price target on Quipt Home Medical (QIPT) to C$6.70 from C$7 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QIPT:
- Quipt Home Medical’s Insider Trading Silence Raises Transparency Concerns
- Quipt Home Medical Reports Q1 2025 Financial Results with Improved EBITDA
- Quipt Home Medical reports Q1 revenue $61.4M, consensus $89.07M
- Is QIPT a Buy, Before Earnings?
- Quipt Home Medical Reaffirms Commitment Amid Proxy Challenge